1st Apr 2019 14:02
LONDON (Alliance News) - Renalytix AI PLC on Monday said a recent study showed that combining its three biomarkers along with health records data improved the prediction of rapid kidney function decline compared to standard methods.
Shares in Renalytix were up 8.1% at 154.00 pence on Monday.
Renalytix develops products that use artificial intelligence to make a more precise diagnosis of kidney disease. The study included 1,369 patients, including 871 patients with type-2 diabetes and 498 patients of African ancestry.
The study combined Renalytix's sTNFR 1, sTNFR2 and KIM-1 biomarkers with data from electronic health records to create a machine learning tool.
In patients with type-2 diabetes, or who are of African ancestry and have a variation in their APOL1 gene associated with kidney disease, this machine learning tool significantly improved prediction of rapid kidney function decline compared to standard clinical models and models that did not use biomarkers.
In machine learning, computers use algorithms and statistical models to complete a task. The algorithms used in the study are key to Renalytix's kidney disease diagnostic product, KidneyIntelX.
Renalytix has begun a multi-centre clinical validation study which will include 5,000 blood samples from patients as well as patient electronic health records from the Icahn School of Medicine at Mount Sinai, as well as from the University of Pennsylvania and Emory University.
Renalytix expects a commercial launch of KidneyIntelX in the US after the 5,000 sample study is complete.
Related Shares:
Renalytix Plc